Trial Profile
The Efficacy of Topically Applied Mesalazine Sustained-Release Tablets in Oral Lesions of Crohn's Disease
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 06 Feb 2023
Price :
$35
*
At a glance
- Drugs Mesalazine (Primary) ; Riboflavin
- Indications Crohn's disease; Oral ulcer
- Focus Therapeutic Use
- 30 Jan 2023 Status changed from recruiting to withdrawn prior to enrolment.
- 04 Jan 2018 New trial record